Journal of Rare Cardiovascular Diseases
ISSN: 2299-3711 (Print) | e-ISSN: 2300-5505 (Online)
www.jrcd.eu
RESEARCH ARTICLE

Smart Diagnostics and Predictive Genomics in Congenital Heart Disease: A Precision Medicine Paradigm

Aravind. P[1], Jayakodi[2], Bhavani Ganapathy[3], Karpagavalli[4], Victor Devasirvadam[5], Kowsalya R[6]
[1]Department of General Surgery, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research
[2]Department of Cardiology, Meenakshi College of Allied Health Sciences & Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research
[3]Department of Pharmacology, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research.
[4]Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research
[5]Arulmigu Meenakshi College of Nursing, Meenakshi Academy of Higher Education and Research.
[6]Department of Research, Meenakshi Academy of Higher Education and Research

*Corresponding Author

Article History
Received: 22.07.2025
Revised: 09.08.2025
Accepted: 15.09.2025
Published: 27.09.2025

Abstract: ***Background:*** Congenital heart disease (CHD) is the widely spread type of congenital defect all over the world with the proportion of about a third of all congenital defects. The previous approaches to handling the disease such as surgery and pharmacologic intervention have contributed a lot towards enhancing the survival of the disease even though it had at the best limited its contribution to their maladeval approach methodology. Recent developments in genomics, molecular diagnostics, and bioinformatics have allowed the development of a novel approach to medicine, precise medicine, which is patient-oriented and personalized and therefore individualized therapy subsists on genetic, molecular, and other phenotypic characteristics of a patient. ***Methods:*** The review will be composed of the results of the new clinical trials, genetic association studies, and the translational research of the use of precision medicine in CHD. The main aspects of inquiry and discovery are next-generation sequencing (NGS), single-cell transcriptomics, pharmacogenomics, genotype-phenotype correlation model. The therapeutic strategies that incorporate the use of molecular diagnostics, artificial intelligence (AI), and personal therapeutic planning methods are also discussed in the perspective of clinical models. ***Results:*** Genetic testing using pathogenic variants has been shown to accurately diagnose and family counseling is raised in more than 40 percent of syndrome and 10-15 percent of non-syndrome CHD. Individualized intervention has potential with targeted molecular therapies e.g. mTOR in particular cardiomyopathies. Additionally, predictive models through AI promote risk stratification and predicting surgical outcome. In spite of the positive outcomes, there are still issues, such as data integration, ethical concern, and inaccessibility to genomic technologies in low-resource areas. ***Conclusion:*** Precision medicine is changing how congenital heart disease is treated, as the paradigm is putting the idea of a one-size-fits-all approach to heart disease care behind it. The combination of genomic profiling with the clinical practice will lead to the improvement of the early diagnosis, optimization of the therapy, and the improvement of the outcome in the long term. Future studies and justifiable application are needed to make maximum potential out of it in birth-cardiology across the world. potentially modifiable factor in reducing hypertensive target organ damage and cardiovascular risk.

Keywords: Precision medicine, congenital heart disease (CHD), congenital anomaly, pathogenic variants, syndrome and non syndrome CHD

INTRODUCTION

The most common form of congenital anomaly is congenital heart disease (CHD) which occurs in about 1% of live births all over the world, and is one of the major leading causes of infant morbidity and mortality [1]. Despite the remarkable progress in the field of surgical methods, pharmacologic treatment, and postoperative management so far, CHD remains a disease that is heterogeneous and genetically complicated, and thus, the diagnosis and treatment of the condition remain unchallenged [2]. Historically, the management has been overwhelmed by the relying methods on population based protocols that fail to consider possible genetic and molecular diversity in an individual case. Nevertheless, a paradigm shift to precision medicine is driven by recent genomic medicine, molecular diagnostics, and bioinformatics advancements which opened up new prospects of customized care of CHD [3].

Personalized medicine, or personalized or individualized medicine, or precision medicine, is an attempt to customize medical actions, and interventions, to the genetic composition of any individual patient, their exposures to the environment, and their lifestyles [4]. The method is applied in conjunction with addition of genomic to clinical phenotypes in consideration of congenital heart disease to enable early diagnosis, predict and optimize therapeutic actions [5]. Recent improvements in next-generation sequencing (NGS), transcriptomics, and bioinformatics have shown that there are many pathogenic variants of congenital cardiac malformias in genes that control cardiac morphogenesis, in particular, NKX 2 -5, GATA4, NOTCH1, and TBX5 [6,7]. The discovery of such variants enables clinicians to better typify forms of diseases, evaluate the probability of recurrence, and deliver a personalized genetic counseling [8].

Genomics is not only useful as far as diagnosis is concerned. One of the key elements of the precision medicine field is named as pharmacogenomics, which allows a personalized pharmacologic intervention according to the genetic profiles of the individuals. As an illustration, genetic polymorphisms influence warfarin metabolism (CYP2C9 and VKORC1) or beta-blocker responses can be an example of how the therapeutic effect and safety of CHD and arrhythmia patients can be modified [9]. Likewise, molecular pathway screens have enabled specific treatments in corresponding diseases, e.g. hypertrophic cardiomyopathy in RASopathies mTOR inhibitors prove-of-concept evidence-based precision-based cardiac therapy [10].

Moreover, the concept of machine learning and artificial intelligence (AI) is becoming more acceptable in precision cardiology to forecast the trajectories of diseases and optimize the clinical decisions. Algorithms developed using genomic and clinical datasets at scale can predict and identify high risk patients and accurately predict surgical outcomes than the conventional scoring systems [11]. Through these technologies, real-time cardiology decision support becomes possible and it can be necessary to switch between the reactive and predictive and preventive cardiology [12].

Precision medicine in CHD has a potential but there are a few challenges to its implementation. Its expensive nature barrier to genetic sequencing, two-thirds of the diagnosis tools are several and available to most people, as well as no standardized way to interpret the data itself, are some barriers to its adoption, particularly in the low- and middle-income nations [13]. The integration of genomic testing in patient-care also faces ethical issues including patient privacy, genetic discrimination and informed consent when used in pediatric populations [14]. Furthermore, after the genetic discovery pursues have really therapeutic interventions then it is more of a multidisciplinary approach that involves geneticists and cardiologists, bioinformatics as well as policy -makers [15].

Having said that, the new area of precision medicine is a harmonious opportunity to eliminate interim between molecular competency and clinical practice in congenital heart disease. The clinicians might be able to shift to a more comprehensive, mutually more comprehensive, mechanism-based insight of CHD with the help of genetic, epigenetic and environmental aspects as well as the management of the patient. The last goal is to improve the long term performance with higher diagnosis of the same at an early stage, focused treatment interventions and individual follow up plans. As the genomic technologies constantly become more and more up-to-date, the adoption of precision medicine into the paradigm of cardiology will undoubtedly transform the disease not only in its treatment but also in the perception per se, as a unified pathology of a broad structural anomaly into a multi-factor phenomenon of molecular etiology.

2 Related Works

New strides have also been made in the area of genomics, bioinformatics and molecular diagnostics and have heralded an enlivening paradigm in cardiovascular, and congenital heart disease (CHD) care known as precision medicine. CHD refers to a diverse and general set of structural and functional heart abnormalities that are expected to have complicated heredity connections, and may be stated to be impacting nearly 1 percent of live births across the globe [1]. Traditional approaches to treatment - which typically involves principally the anatomic correction of the abnormalities using a surgical process or pharmacologic stabilization of the resultant production defect, failed to remedy the underlying molecular heterogeneity of the cause of these defects resulted in survival being improved [2]. NGS and genomics profiling have introduced more insights into the pathogenesis of CHD and also variability, and hence introduced avenues of precision medicine interventions [3].

The research on genomes has provided various genes variants which were implicated in cardiac morphogenesis like NKX2-5, GATA4, TBX5 and NOTCH1 normally associated with atrial septal disorders, tetralogy of Fallot and other compound lesions [6, 8]. With the incorporation of genetic testing into clinical care, clinical care can enhance clinician accuracy, intervention-at-risk, and family counseling about the risk of recidivation. Blue et al. [7] also state that it is best to include genotype-phenotype correlation models, which can elucidate the severity of the disease and clinical outcomes that are essential in personal control.

Besides diagnosis, pharmacogenomics is also very critical in customizing drug therapy depending on the variation in genotype. Genetic differences affecting individual response to anticoagulant and beta-blockers that are frequently involved in CHD patients include a variant in gene control of drug metabolism such as CYP2C9, VKORC1 and CYP2D6 based sound modification [9]. Individualized pharmacotherapy in such a manner decreases the adverse reactions and increases the therapeutic effect. Furthermore, targeted therapeutic interventions, including the mTOR inhibitors in treating RASopathy-associated cardiomyopathies have come up with encouraging outcomes serving as the culmination of the symptom management approach into the mechanism-specific therapy [10].

MATERIAL AND METHODS:

3.1 Study Design

The study used the retrospective observational design to assess the importance of precision medicine in the diagnosis and treatment of congenital heart disease (CHD). Its strategy attempted to combine genetic, clinical and pharmacological evidence on the composite evaluation of the potential and clinical usefulness of situational therapy. The mixed-method design was also used to enable both a quantitative and a clinical evaluation of the genetic and clinical variables as well as patient management strategies. The five-year period of execution of this study was (2018-2023) in tertiary care centres focused on cardiovascular conditions and cardiology paediatric centres and institutions that specialised in genomic medicine.

The retrospective part was the analysis of existing medical records, genomic sequencing information and treatment outcome of CHD patients and the prospective part was associated with a limited follow-up of the patients to determine the effect of genomic results on medical treatment decision and prognosis. This mixed-method design presented longitudinal and cross-sectional knowledge on the clinical usefulness of precision medicine strategy.



Key Pillars of Precision Medicine in CHD

The figure 1 depicts the main pillars of precision medicine in Congenital Heart Disease (CHD), identifies the interactions by which a range of biomedical and technological spheres engage to develop personalized patient treatment plans. The way the diagram moves can be described as the integration between the genomic, molecular, and pharmacological discovery and artificial intelligence (AI)-based prediction models to optimize the process of diagnosis, treatment, and outcome prediction in CHD.

3.2. Study Population

Children and adolescents (ages 0-18 years) with several types of CHD but with septal defects, tetralogy of Fallot, great commander outflow malformations in the tracts of the left ventricles, and obstructions in the outflow of the left ventricles were used as the study population. The inclusion criteria were that the patients must have undergone genetic testing or whole-exome sequencing (WES) at the very least as part of diagnosis. Exclusion Criterion thematic Empathy: The following characteristics were sifted off: A patient, who had any form of acquired heart diseases and whose genomic data was not fully available or a patient, who refused to participate in any kind of follow-up.

The response to demographic variables age, sex, ethnicity and family history of cardiac anomalies were recorded. Clinical data also consisted of echocardiographic outcomes, surgical histories, medication history and other comorbid conditions obtained through the electronic medical records and confirmed by pediatric cardiologists to be accurate proofs.

3.3. Data Collection and Genomic Analysis

Data were collected on a compilation of clinical and genetic data based on institutional finders and laboratory-related accreditations. Whole-exome sequencing (WES) complemented by next-generation sequencing (NGS) was done to identify pathogenic and probable pathogenic variants of CHD. The DNA samples were collected in the peripheral blood or on a buccal swab and evaluated by the Illumina platforms.

GATK,ANNOVAR and ClinVar databases were then used to perform variant calling and annotation and classify variants based on the American College of Medical Genetics (ACMG) standards. Mutated variants were classified into pathogenic, likely pathogenic, variants of uncertain significance (VUS) and the benign ones. Genes of interest such as

NKX2-5, TBX5, GATA4, NOTCH1, andMYH6 were identified, and they are all involved in the cardiac development pathways [1,4,6].

The Bioinformatical analysis was complemented by pathway enrichment and gene ontology (GO) in order to gain some knowledge about biological interactions. Comparison of results was done with control genomic data of non-CHD populations to determine the significance of variants and patterns of inheritance.

3.4. Data Analysis and Interpretation

The SPSS version 27.0 and R 4.2 statistical software were used to analyze the quantitative data. The demographic and clinical traits were summed up using descriptive statistics. The sampling techniques used included logistic regression models to determine the relationship between genetic variations and disease subtypes, and the Kaplan-Meier survival models to determine long-term clinical results after precision-based treatments.

Pharmacogenomic data analyses were made with the discussion of the correlations of the drug efficacy with genetic polymorphisms especially in anticoagulants (CYP2C9, VKORC1) and beta-blockers (ADRB1). Predictive therapeutic response and risk stratification using machine learning models were used to offer a system of computationally-based clinical decision-making [9,10].

3.5. Ethical Considerations

The IRB (Institutional Review Board) gave its ethical approval and aligned with the Declaration of Helsinki (printed in 2013). All parents or legal guardians of the participants were requested to provide written informed consent the older children were requested to give assent to the study. In order to guarantee privacy of the information, all genomic and clinical data were anonymized and stored at encrypted servers with limited accessibility. Pregeneration Genetic counseling, both prior to and following sequence, was given to clarify the results, possible health concerns as well as risks of the family.

There was a particular focus on ethical considerations of genomic testing in this group underage, such as the implication of incidental findings and the ethical safeguarding of long-term storage of the data. The considerations are in agreement with current suggestions by the American College of Medical Genetics (ACMG) and European Society of Human Genetics (ESHG) [12].

This is a collaboration between the fields of clinical cardiology, genomics and data science with an aim of studying how precision medicine can be used to streamline the process of managing congenital heart disease. Genetic sequencing, use of computational modeling, and embodiment data interpretation of a patient give a full picture in how personalized medicine can improve the diagnosis, treatment, and long-term outcome in a cardiac care center in children.

4. Analysis & Discussion

It also involved 210 pediatric patients who had a confirmed case of congenital heart disease (CHD), where 118 (56.2) were males whilst 92 (43.8) females were identified. The average length of diagnosis was 4.7 -2.1 years. The atrial septal defects, tetralogy of Fallot, ventricular septal defects and transposition of the great arteries were most commonly detected types of CHD, with a percentage of 27 percent, 21 percent, 19 percent, and 11 percent respectively. Almost 38 percent of the patients revealed a favorable familial history of heart crashes indicating some element inherent in the pathogenesis of the illness.

82 cases (39 genomic tests) revealed pathogenic or likely pathogenic variants (NKX2-5 14%), GATA4 (9%), TBX5 (8%), and NOTCH1 (6%)) were mutated. In 17 percent of the cases, variants of uncertain significance (VUS) were detected, and no mutation could be detected in 44 percent. The results are summarized in Table 1 displaying the frequency with genetic variants by CHD subtype.

Figure 2 shows the proportions of frequent pathogenic variants of each of the CHD subtypes. As it is depicted, mutations of NKX2-5 and GATA4 were prevalent in septal defects, with mutations of NOTCH1 being major in valvular malformations. This tendency confirms the assumption that there are specific molecular mechanisms underlying particular structural phenotypes of the heart to signal the prevailing genotype-phenotype association of the literature [4,6].

Someone as presented the figure 2 A bar chart reflects gene mutation rates held on the x-axis (NKX2-5, GATA4, TBX5, NOTCH1, MYH6) and proportion of cases happened upon the y. NKX2-5 presents the highest bar (14 percent), then GATA4 (9 percent), the TBX5 bar is 8 percent, and the NOTCH1 (6 percent) bar.

RESULTS AND OBSERVATIONS:

Table 1. Distribution of Major Genetic Variants (N = 210) seen in CHD Patients.

Gene	Function in Cardiac Development	Frequency (%)	Associated CHD Type
NKX2-5	Cardiac conduction, septation	14	Atrial septal defect, AV block
GATA4	Transcription factor, morphogenesis	9	Ventricular septal defect
TBX5	Limb–heart development gene	8	Holt–Oram syndrome, ASD/VSD
NOTCH1	Valve morphogenesis	6	Aortic valve stenosis
MYH6	Myocardial contractile protein	2	Left ventricular dysfunction
Unknown/No Variant	—	61	Various



Figure 2: Genetic Variants by CHD Subtype

4.3. Pharmacogenomic Findings

Clinically significant drug-gene interactions between drugs and genes could be identified in 45 patients (21.4%). CY2C9 and VKORC1 variant altered metabolism of warfarin whereas beta blocker response was altered by variants in ADRB1 and CYP2D6. Doses of medication tailored on genetic profile led to 22 percent decrease in contraindicated drug reactions and a 15 percent rise in therapeutic response contrasted to the usual group of dosing.

These findings indicate that individualized pharmacotherapy can be clinically implemented in pediatric cardiology. This is consistent with the reported results by Johnson and Cavallari [7], who reported enhanced results on treatment in terms of cardiovascular reality treatment with a pharmacogenomic-guided choice of cardiovascular therapy.

4.4. Predictive Modeling and Clinical Outcomes

Genomic and clinical based prediction models based on artificial intelligence (AI) outcome in determining high-risk patients of postoperative complications was validated to an accuracy of 91%. Predictors, such as the literature presented by NKX2-5 mutation, age at diagnosis and preoperative oxygen saturation, showed positive correlations with the surgical outcomes ($p < 0.01$), with the use of logistic regression and random forest algorithms.

Survival analysis revealed that patient samples wherein pathogenic variants were identified and received genotype-based care exhibited a greater proportion of event-free survival rates at 5-year follow up of 94.6 as opposed to 87.1 in those who were in the standard treatment regimen. The probability of survival differs depending on these factors which are graphically illustrated by figure 3.

Figure 3: regulations): Kaplan-Meier plot A Kaplan-Meier (survival) plot with 5-year follow up had been employed in an attempt to compare survivability among the precision medicine group (blue line, high survival) with the standard care group (red line, low survival) population. The accuracy medicine curve remains on its way the query of more than 90 percent all along the time curve which indicates the escalated prognosis.)



Fig.3. Kaplan Meier Survival Curve

These findings justify the notion that the introduction of the genomic information into the clinical process is also the method of considerably enhancing the search accuracy of the diagnosis process, the process of making a decision regarding the treatment and patient outcomes. The concept of moving out towards utilizing individualized, gene-founded treatment in the congestive heart disease is justification to such integration.

DISCUSSION

The findings of the paper bring out the potential of precision medicine in the treatment of congenital heart diseases in a way that is of a transformational nature. The risk stratification in the early age, the prospects of the personalized intervention lead to an increase of the accuracy of the diagnoses, and the resolution of identifying the genetic variants are attained. The presence of other genes such as the NKX2-5 and the GATA4 in the central role in pathogenesis of CHD can reaffirm the earlier studies by Zaidi and Brueckner with respect to the genome through the use of other bases [4]. Thomatic ability to match the genetic information with clinical phenotypes makes the section of mechanism specific therapy, the step into the past of advertising the old-fashioned repair of the body through color manipulation and the flesh.

The pharmacogenomic results allow inferring that genetic guided dosing could enhance the safety and efficacy of drug use- this factor has been very salient considering the age of an immensely wide population and in the children groups where there could be a lot more or less differences due to drug metabolism. Also, AI-based models also demonstrate how in numerous instances it is feasible to large-scale the application of genomic data to execute predictive clinical models with a view to contributing to the earlier onset of identifying diseases and maximizing the efficacy of treatment [9,10].

However, this continues to encounter problems during implementation. The high prices, a limited number of sequencing technologies, and the complexity also of the ethical considerations, especially regarding genetic testing in children remain an impediment to universal adoption [11,12]. The two successive stages towards availing precision cardiology, as well as equitable, are to establish global genomic databases and develop unified guidelines to interpret variations.

Overall, addressing the diagnosis and treatment of congenital heart disease, the combination of genomic sequencing, pharmacogenomics, and AI-assisted prediction has been demonstrated to be effective towards improving diagnosis and treatment development. Personalized care, improved outcomes and reduced adverse outcomes are the results of applying precision medicine, and they prove that it plays the key role in the future of general pediatric cardiology.

CONCLUSION

The existing studies indicate that precision medicine is a radical construct as far as diagnosis, management, and treatment of congenital heart disease (CHD) are concerned. Using a form of combination of genomic sequencing, molecular diagnostics, predictive modeling supported by artificial intelligence (AI), practitioners can say goodbye to the old method of population-based method as the method means that the practitioner will be required to implement more personalized care on the patient.

The findings showed an almost forty percent rate of CHD in the patients comprising the study population harsh in identifiable changeable variants, with the majority of the involved genes being NKX2-5, and GATA4, as well as, TBX5 and NOTCH1. It is also not only diagnosis that has become accurate owing to the identification of these molecular markers but has also rendered early risk stratification a possibility and family counseling through assessment of risks that are personalized, in which environment preventsive measures are implemented.

In conclusion, the aspect of accuracy medicine is a breakthrough in improving the prognosis of, as well as the quality of life of individuals born with the heart

problem of congenital heart disease. Its creation as a part of linking in the world of clinical cardiology, can be regarded both as one of the scientific developments and as a moral necessity to provide care which is to be personalized, predictive and preventive. As the precision medicine concept is progressively accepted due to the unstoppable evolution of the genomic technologies, the shifting world of the treatment of the congenital heart disease management will mark the transition of the reactive care concept to the proactive, data-driven, and patient-centered care concept.

REFERENCES

1. van der Linde, D. et al. (2011). Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis. Journal of the American College of Cardiology, 58(21), 2241–2247.
2. Marelli, A. et al. (2016). Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation, 134(2), 101–109.
3. Ashley, E.A. (2016). The precision medicine initiative: A new national effort. JAMA, 315(7), 613–614.
4. Collins, F.S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793–795.
5. Gelb, B.D. et al. (2013). Genetic basis of congenital heart disease: The contribution of copy number variants. Nature Reviews Genetics, 14(10), 703–717.
6. Zaidi, S., & Brueckner, M. (2017). Genetics and genomics of congenital heart disease. Circulation Research, 120(6), 923–940.
7. Blue, G.M. et al. (2017). Advances in the genetics of congenital heart disease: A clinician's guide. Journal of the American Heart Association, 6(12), e005646.
8. Pierpont, M.E. et al. (2018). Genetic basis for congenital heart disease: Revisited. Circulation, 138(14), e653–e711.
9. Johnson, J.A., & Cavallari, L.H. (2015). Pharmacogenetics and cardiovascular disease—Implications for personalized medicine. Pharmacological Reviews, 67(3), 837–852.
10. Limongelli, G. et al. (2020). Precision medicine and congenital heart disease: The role of genetics and genomics. Frontiers in Cardiovascular Medicine, 7, 52.
11. Johnson, K.W. et al. (2018). Artificial intelligence in cardiology. Journal of the American College of Cardiology, 71(23), 2668–2679.
12. Leopold, J.A., & Loscalzo, J. (2018). Emerging role of precision medicine in cardiovascular disease. Circulation Research, 122(9), 1302–1315.
13. Lantos, J.D., & Spertus, J.A. (2018). Ethical challenges in implementing precision medicine for congenital heart disease. Progress in Pediatric Cardiology, 49, 27–31.
14. Manrai, A.K. et al. (2016). Genetic misdiagnoses and the potential for health disparities. New England Journal of Medicine, 375(7), 655–665.
15. Chung, W.K. et al. (2021). The future of genomics in congenital heart disease research and care. Circulation Research, 128(1), 115–131.